Demographics and baseline characteristics
| . | Ruxolitinib plus siremadlin 20 mg (n = 7) . | Ruxolitinib plus siremadlin 30 mg (n = 10) . | Ruxolitinib plus siremadlin 40 mg (n = 6) . | Ruxolitinib plus siremadlin total (N = 23) . |
|---|---|---|---|---|
| Age, median (range), y | 72 (59.0-78.0) | 64 (37.0-77.0) | 75.5 (59.0-86.0) | 68 (37.0-86.0) |
| Male gender, n (%) | 5 (71.4) | 4 (40.0) | 6 (100) | 15 (65.2) |
| Initial diagnosis of disease, n (%) | ||||
| Post–ET MF | 1 (14.3) | 0 | 0 | 1 (4.3) |
| Post–PV MF | 0 | 4 (40.0) | 3 (50.0) | 7 (30.4) |
| Primary MF | 6 (85.7) | 6 (60.0) | 3 (50.0) | 15 (65.2) |
| Time since initial diagnosis, median (range), mo | 34.3 (10.0-115.1) | 130.5 (11.5-264.4) | 108.3 (16.6-517.6) | 52.8 (10.0-517.6) |
| Baseline Hb level, median (range), g/L | 92.0 (77.0-108.0) | 94.0 (62.8-111.0) | 90.6 (73.0-103.1) | 91.0 (62.8-111.0) |
| Baseline ANC, median (range), 109/L | 3.0 (1.7-25.7) | 3.4 (1.3-15.9) | 6.5 (3.2-11.1) | 4.3 (1.3-25.7) |
| Baseline platelet count, median (range), 109/L | 193.0 (85.0-586.0) | 167.0 (77.0-319.0) | 130.5 (90.0-574.0) | 160.0 (77.0-586.0) |
| Spleen palpable at baseline, n (%) | 5 (71.4) | 9 (90.0) | 6 (100) | 20 (87.0) |
| Baseline spleen length below LCM, median, cm∗ | 5.0 | 11.0 | 12.0 | 11.0 |
| Baseline spleen volume (CT/MRI), median, mL | 560.0 | 2279.6 | 2935.7 | 1940.4 |
| Baseline MFSAF TSS, median (range) | 9.0 (4.0-23.0) | 13.0 (0.0-45.0) | 10.5 (2.0-23.0) | 12.0 (0.0-45.0) |
| Prior ruxolitinib duration, median (range), wk | 46.3 (27.0-228.0) | 165.1 (47.3-305.4) | 47.3 (19.7-493.7) | 67.9 (19.7-493.7) |
| . | Ruxolitinib plus siremadlin 20 mg (n = 7) . | Ruxolitinib plus siremadlin 30 mg (n = 10) . | Ruxolitinib plus siremadlin 40 mg (n = 6) . | Ruxolitinib plus siremadlin total (N = 23) . |
|---|---|---|---|---|
| Age, median (range), y | 72 (59.0-78.0) | 64 (37.0-77.0) | 75.5 (59.0-86.0) | 68 (37.0-86.0) |
| Male gender, n (%) | 5 (71.4) | 4 (40.0) | 6 (100) | 15 (65.2) |
| Initial diagnosis of disease, n (%) | ||||
| Post–ET MF | 1 (14.3) | 0 | 0 | 1 (4.3) |
| Post–PV MF | 0 | 4 (40.0) | 3 (50.0) | 7 (30.4) |
| Primary MF | 6 (85.7) | 6 (60.0) | 3 (50.0) | 15 (65.2) |
| Time since initial diagnosis, median (range), mo | 34.3 (10.0-115.1) | 130.5 (11.5-264.4) | 108.3 (16.6-517.6) | 52.8 (10.0-517.6) |
| Baseline Hb level, median (range), g/L | 92.0 (77.0-108.0) | 94.0 (62.8-111.0) | 90.6 (73.0-103.1) | 91.0 (62.8-111.0) |
| Baseline ANC, median (range), 109/L | 3.0 (1.7-25.7) | 3.4 (1.3-15.9) | 6.5 (3.2-11.1) | 4.3 (1.3-25.7) |
| Baseline platelet count, median (range), 109/L | 193.0 (85.0-586.0) | 167.0 (77.0-319.0) | 130.5 (90.0-574.0) | 160.0 (77.0-586.0) |
| Spleen palpable at baseline, n (%) | 5 (71.4) | 9 (90.0) | 6 (100) | 20 (87.0) |
| Baseline spleen length below LCM, median, cm∗ | 5.0 | 11.0 | 12.0 | 11.0 |
| Baseline spleen volume (CT/MRI), median, mL | 560.0 | 2279.6 | 2935.7 | 1940.4 |
| Baseline MFSAF TSS, median (range) | 9.0 (4.0-23.0) | 13.0 (0.0-45.0) | 10.5 (2.0-23.0) | 12.0 (0.0-45.0) |
| Prior ruxolitinib duration, median (range), wk | 46.3 (27.0-228.0) | 165.1 (47.3-305.4) | 47.3 (19.7-493.7) | 67.9 (19.7-493.7) |
ANC, absolute neutrophil count; CT, computed tomography; ET, essential thrombocythemia; Hb, hemoglobin; LCM, left costal margin; MRI, magnetic resonance imaging.
Baseline spleen length is summarized for patients with palpable spleen.